About Efung Capital

Shenzhen Efung Capital, one of the earliest VC/PE companies in China, focuses on the investment of biopharmaceutical and medical device companies. Efung has invested about 20 new drug and medical device companies in China and internationally. Of which, Chipscreen (Shenzhen) marketed an anti-cancer new drug, Chidamide, in 2015; Frontier Biotech(Nanjing)will market Albuvirtide within months, which could become one of the world's first long-acting anti-HIV new drug ever approved; Ascentage Pharma (Jiangsu) and Gmax Biopharm (Hangzhou) will be IPO in NASDAQ in 2018. Since 2015, Efung initiated two U.S. Dollar Fundings and already invested 5 Pharmaceutical companies, such as Aridis, Reservlogix, Centrexion, et.al. We collaborate with many individual and institution investors, public listed pharmaceutical/medical device companies, investing banks and governmental agents from China, and internationally.

Therapeutic Areas

Cardiovascular Infectious Metabolic Oncology

Technologies

Antimicrobial Diagnostics Drug delivery Regenerative medicine

Company Type

Investor

State of Ownership

Private

Sponsorship Group

Networker

Topics

Editions participated in:

June 2018